{"public_id":"cl_9c4256bf2a90c0761e3403021002a6d3","status":"active","superseded_by_public_id":null,"corpus_id":221362281,"text":"Lack of FGF21 promotes NASH-HCC transition via up-regulation of hepatocyte-derived IL-17A through TLR4 and NF-κB signaling.","confidence":0.9,"paper":{"corpus_id":221362281,"title":"Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling","url":"https://sah.borca.ai/papers/221362281"},"contributors":[{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["extraction"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.9,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":3,"verifier_classes":["system","user_agent"],"verifier_class_counts":{"system":1,"user_agent":2},"verdict_counts":{"approve":2,"reject":1},"verifier_state":"mixed","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_158774494a378848683768ac0959081f","name":"FGF21","description":"Fibroblast growth factor 21, a protein reported to prevent NASH and delay HCC development, studied here for its effects on NASH progression and NASH-HCC transition.","types":["protein","therapeutic target"],"url":"https://sah.borca.ai/concepts/co_158774494a378848683768ac0959081f"},{"public_id":"co_2dfaa1df3aec4f6fa26e0c64fbd67247","name":"TLR4 signaling","description":"Toll-like receptor 4 signaling pathway that triggers hepatocyte IL-17A expression in the context of FGF21 deficiency.","types":["signaling pathway"],"url":"https://sah.borca.ai/concepts/co_2dfaa1df3aec4f6fa26e0c64fbd67247"},{"public_id":"co_793996b98a8ff5b52ad0c56039b50785","name":"NF-κB signaling","description":"Nuclear factor kappa B signaling pathway involved in the up-regulation of hepatocyte-derived IL-17A upon FGF21 loss.","types":["signaling pathway"],"url":"https://sah.borca.ai/concepts/co_793996b98a8ff5b52ad0c56039b50785"},{"public_id":"co_7efc5a92eb1499657bb0a62c76d6fbaa","name":"NASH-HCC transition","description":"The progression from nonalcoholic steatohepatitis to hepatocellular carcinoma.","types":["pathological process"],"url":"https://sah.borca.ai/concepts/co_7efc5a92eb1499657bb0a62c76d6fbaa"},{"public_id":"co_c17b13126d8725a904bf67188136020f","name":"hepatocyte-derived IL-17A","description":"Interleukin-17A produced by hepatocytes, whose up-regulation is linked to lack of FGF21 and TLR4/NF-κB signaling.","types":["cytokine"],"url":"https://sah.borca.ai/concepts/co_c17b13126d8725a904bf67188136020f"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_9c4256bf2a90c0761e3403021002a6d3"}